Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 784K
2: EX-10.1 Material Contract HTML 388K
3: EX-10.2 Material Contract HTML 55K
4: EX-10.3 Material Contract HTML 30K
5: EX-10.4 Material Contract HTML 30K
6: EX-10.5 Material Contract HTML 149K
7: EX-10.6 Material Contract HTML 43K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
17: R1 Cover Page HTML 75K
18: R2 Condensed Consolidated Balance Sheets HTML 115K
19: R3 Condensed Consolidated Balance Sheets HTML 39K
(Parenthetical)
20: R4 Condensed Consolidated Statements of Income HTML 88K
21: R5 Condensed Consolidated Statements of Comprehensive HTML 38K
Income (Loss)
22: R6 Condensed Consolidated Statements of Comprehensive HTML 25K
Income (Loss) (Parenthetical)
23: R7 Condensed Consolidated Statements of Stockholders' HTML 59K
Equity
24: R8 Condensed Consolidated Statements of Cash Flows HTML 87K
25: R9 Organization and Summary of Significant Accounting HTML 39K
Policies
26: R10 Revenues HTML 100K
27: R11 Collaboration Agreements And In-Licensing HTML 52K
Arrangements
28: R12 Cash and Investments HTML 98K
29: R13 Forward Currency Contracts HTML 25K
30: R14 Fair Value Measurements HTML 57K
31: R15 Inventory HTML 35K
32: R16 Stock-Based Compensation HTML 47K
33: R17 Provision For (Benefit From) Income Taxes HTML 26K
34: R18 Net Income Per Share HTML 40K
35: R19 Commitments and Contingencies HTML 29K
36: R20 Organization and Summary of Significant Accounting HTML 61K
Policies (Policies)
37: R21 Revenues (Tables) HTML 101K
38: R22 Collaboration Agreements And In-Licensing HTML 43K
Arrangements (Tables)
39: R23 Cash and Investments (Tables) HTML 110K
40: R24 Fair Value Measurements (Tables) HTML 54K
41: R25 Inventory (Tables) HTML 35K
42: R26 Stock-Based Compensation (Tables) HTML 45K
43: R27 Net Income Per Share (Tables) HTML 42K
44: R28 Organization and Summary of Significant Accounting HTML 32K
Policies (Details)
45: R29 Revenues - Revenues by Disaggregated Category HTML 40K
(Details)
46: R30 Revenues - Revenues Disaggregated by Significant HTML 47K
Customer (Details)
47: R31 Revenues - Revenues Disaggregated by Geographic HTML 33K
Region (Details)
48: R32 Revenues - Net Product Revenues Disaggregated by HTML 33K
Product (Details)
49: R33 Revenues - Activities and Ending Reserve Balances HTML 44K
for Significant Categories of Discounts and
Allowances (Details)
50: R34 Revenues - Contract Assets and Liabilities HTML 39K
(Details)
51: R35 Collaboration Agreements And In-Licensing HTML 36K
Arrangements - Collaboration Revenues under the
Collaboration Agreement with Ipsen (Details)
52: R36 Collaboration Agreements And In-Licensing HTML 26K
Arrangements - Ipsen Collaboration Narrative
(Details)
53: R37 Collaboration Agreements And In-Licensing HTML 36K
Arrangements - Collaboration Revenues under the
Collaboration Agreement with Takeda (Details)
54: R38 Collaboration Agreements And In-Licensing HTML 26K
Arrangements - Takeda Collaboration Narrative
(Details)
55: R39 Collaboration Agreements And In-Licensing HTML 29K
Arrangements - GSK (Details)
56: R40 Collaboration Agreements And In-Licensing HTML 32K
Arrangements - Royalty Revenues under the
Collaboration Agreement with Genentech (Details)
57: R41 Collaboration Agreements And In-Licensing HTML 34K
Arrangements - In-Licensing Collaborations
(Details)
58: R42 Cash and Investments - Reconciliation of Cash, HTML 32K
Cash Equivalents, and Restricted Cash (Details)
59: R43 Cash and Investments - Investments by Security HTML 71K
Type (Details)
60: R44 Cash and Investments - Narrative (Details) HTML 33K
61: R45 Cash and Investments - Fair Value and Gross HTML 38K
Unrealized Losses of Investments
Available-for-Sale in an Unrealized Loss Position
(Details)
62: R46 Cash and Investments - Fair Value of Cash HTML 31K
Equivalents and Investments by Contractual
Maturity (Details)
63: R47 Forward Currency Contracts (Details) HTML 32K
64: R48 Fair Value Measurements (Details) HTML 69K
65: R49 Inventory (Details) HTML 37K
66: R50 Stock-Based Compensation - Allocated Employee HTML 30K
Stock-Based Compensation Expense (Details)
67: R51 Stock-Based Compensation - Based Compensation HTML 34K
Expense (Details)
68: R52 Stock-Based Compensation - Narrative (Details) HTML 68K
69: R53 Stock-Based Compensation - Estimate Grant-Date HTML 34K
Fair Value (Details)
70: R54 Net Income Per Share - Computation of Basic and HTML 51K
Diluted Net Income Per Share (Details)
71: R55 Net Income Per Share - Potential Shares of Common HTML 27K
Stock Not Included in the Computation of Diluted
Net Income (Loss) Per Share (Details)
73: XML IDEA XML File -- Filing Summary XML 128K
16: XML XBRL Instance -- exel-20210402_htm XML 1.44M
72: EXCEL IDEA Workbook of Financial Reports XLSX 77K
12: EX-101.CAL XBRL Calculations -- exel-20210402_cal XML 192K
13: EX-101.DEF XBRL Definitions -- exel-20210402_def XML 465K
14: EX-101.LAB XBRL Labels -- exel-20210402_lab XML 1.16M
15: EX-101.PRE XBRL Presentations -- exel-20210402_pre XML 716K
11: EX-101.SCH XBRL Schema -- exel-20210402 XSD 134K
74: JSON XBRL Instance as JSON Data -- MetaLinks 292± 434K
75: ZIP XBRL Zipped Folder -- 0000939767-21-000045-xbrl Zip 452K
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D.,
the President and Chief Executive Officer of Exelixis, Inc. (the “Company”), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
1. The Company’s Quarterly Report on Form 10-Q for the period ended April 2, 2021, to which this Certification is attached as Exhibit 32.1 (the “Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.
In Witness Whereof, the undersigned have set their hands hereto as of the 6th day of May 2021.
